µP-TSCPC demonstrated good efficacy and safety profiles with minimal vision-threatening complications in treating a variety of glaucoma types.
No takes yet. Share an insight, caveat, or question.
Habash et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: